IP Verse

Methods Of Treatment For Esophageal Inflammation - EP2585075

The patent EP2585075 was granted to Meritage Pharma on Sep 22, 2021. The application was originally filed on Jun 24, 2011 under application number EP11799004A. The patent is currently recorded with a legal status of "Revoked".

EP2585075

MERITAGE PHARMA
Application Number
EP11799004A
Filing Date
Jun 24, 2011
Status
Revoked
Dec 9, 2022
Grant Date
Sep 22, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR FALK PHARMAMay 4, 2022ADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2009123550
INTERNATIONAL-SEARCH-REPORTUS2009181099
INTERNATIONAL-SEARCH-REPORTUS2011081411
INTERNATIONAL-SEARCH-REPORTWO2009132048
OPPOSITIONEP2585075
OPPOSITIONUS2007111978
OPPOSITIONUS2009123550
OPPOSITIONUS2009181099
OPPOSITIONWO2009132048
OPPOSITIONWO2011163614
SEARCHUS2009123550
SEARCHUS2009181099
SEARCHWO2009132048

Non-Patent Literature (NPL) Citations (5) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Aceves Seema S., Et Al., "Oral Viscous Budesonide: A Potential New Therapy for Eosinophilic Esophagitis in Children", Am J Gastroenterol, (20070101), vol. 102, no. 10, pages 2271 - 2279, XP055865166-
OPPOSITION- Aceves, S.S. ; Dohil, R. ; Newbury, R.O. ; Bastian, J.F., "Topical viscous budesonide suspension for treatment of eosinophilic esophagitis", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20050901), vol. 116, no. 3, ISSN 0091-6749, pages 705 - 706, XP026968506-
OPPOSITION- Dohil, R. ; Newbury, R. ; Fox, L. ; Bastian, J. ; Aceves, S., "Oral Viscous Budesonide Is Effective in Children With Eosinophilic Esophagitis in a Randomized, Placebo-Controlled Trial", Gastroenterology, Elsevier Inc., US, US , (20100801), vol. 139, no. 2, ISSN 0016-5085, pages 418 - 429.e1, XP027399189-
OPPOSITION- Odonnell S., Omorain Colm A., "Therapeutic benefits of budesonide in gastroenterology", Therapeutic Advances in Chronic Disease, (20100101), vol. 1, no. 4, pages 177 - 186, XP055922457-
OPPOSITION- Straumann Alex, Sebastien Conus,Lukas Degen, Stephanie Felder, Mirjam Kummer, Hansjürg Engel, Christian Bussmann, Christoph Beglinger, Alain Schoepfer, Hans-uwe Simon, "Budesonide is effective in adolsecent and adult patients with active eosinophilic esophagitis", Gastroenterology, (20101101), vol. 139, no. 5, pages 1526 - 1537, XP055922461-

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents